相关实验视频
Updated: Sep 20, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
385
用于治疗类风湿性关节炎的免疫抑制性细胞因子绑定水凝
Woojin Back1, Moonkyoung Jeong1, Huyen-Thao Le1
1Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
Advanced healthcare materials
|May 26, 2025
概括
一种新型的介质素-4 (IL-4) 绑定水凝通过减少炎症和关节损伤,有效地治疗小鼠的类风湿性关节炎 (RA). 这种局部治疗为炎症性疾病的系统性免疫抑制提供了一个有希望的替代方案.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致关节炎症和破坏.
- 目前使用一般免疫抑制的RA治疗有局限性和副作用.
- 需要局部化,有针对性的疗法来有效管理RA.
研究的目的:
- 开发和评估用于治疗RA的基于氨酸的凝,以氨酸-4 (IL-4) 连接为基础.
- 评估水凝的免疫调节特性和机械适合于关节内注射.
- 在临床前的RA模型中研究水凝在减轻关节损伤方面的有效性.
主要方法:
- 制造一种IL-4结合的氨酸水凝,其机械性能优化,可用于关节注射.
- 评估水凝促进M2巨细胞两极分化并创造抗炎微环境的能力.
- 在原诱导性关节炎 (CIA) 鼠标模型中评估软骨的保存和关节损伤的缓解.
主要成果:
- 开发的水凝显示出适合于关节内应用的机械性能.
- 水凝成功诱导了M2巨细胞的两极分化,建立了一个抗炎环境.
- 在中情局小鼠模型中,水凝治疗保存了软骨并减少了关节损伤.
结论:
- 与IL-4结合的水凝为类风湿性关节炎提供了一个可行的局部治疗策略.
- 该平台通过调节免疫反应,显示出治疗RA和其他炎症状况的潜力.
- 这项研究强调了先进生物材料在开发针对自身免疫性疾病的向疗法的前景.
相关概念视频
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
01:20The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K